Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Melanoma
  Free Subscription

Articles published in
Int J Cancer
    June 2024
  1. KAMEI M, Matsuo K, Yoshida Y, Shimada K, et al
    Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells.
    Int J Cancer. 2024;154:2176-2188.
    >> Share

    April 2024
  2. FROHLICH LM, Villar-Miyar A, Heintze T, Sauer B, et al
    PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma.
    Int J Cancer. 2024 Apr 15. doi: 10.1002/ijc.34947.
    >> Share

    February 2024
  3. CHELLADURAI M, Xu D, Izraely S, Ben-Menachem S, et al
    A heterodimer of alpha and beta hemoglobin chains functions as an innate anticancer agent.
    Int J Cancer. 2024;154:561-572.
    >> Share

    January 2024
  4. VAN DUIN IAJ, Verheijden RJ, van Diest PJ, Blokx WAM, et al
    A prediction model for response to immune checkpoint inhibition in advanced melanoma.
    Int J Cancer. 2024 Jan 31. doi: 10.1002/ijc.34853.
    >> Share

    December 2023
  5. DINTER L, Karitzky PC, Schulz A, Wurm AA, et al
    BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.
    Int J Cancer. 2023 Dec 11. doi: 10.1002/ijc.34807.
    >> Share

    November 2023
  6. HUERGO-BANOS C, Velasco V, Garate J, Fernandez R, et al
    Lipid fingerprint-based histology accurately classifies nevus, primary melanoma, and metastatic melanoma samples.
    Int J Cancer. 2023 Nov 20. doi: 10.1002/ijc.34800.
    >> Share

  7. TOPE P, Morais S, El-Zein M, Franco EL, et al
    Differences in site-specific cancer incidence by individual- and area-level income in Canada from 2006 to 2015.
    Int J Cancer. 2023;153:1766-1783.
    >> Share

    October 2023
  8. AFSHAR N, Dashti SG, Mar V, Te Marvelde L, et al
    Do age at diagnosis, tumour thickness and tumour site explain sex differences in melanoma survival? A causal mediation analysis using cancer registry data.
    Int J Cancer. 2023 Oct 12. doi: 10.1002/ijc.34752.
    >> Share

    September 2023
  9. ZHANG J, Zhang F, Porter KI, Dakup PP, et al
    Telomere dysfunction in Tert knockout mice delays Braf(V600E) -induced melanoma development.
    Int J Cancer. 2023 Sep 20. doi: 10.1002/ijc.34713.
    >> Share

    July 2023
  10. KRETSCHMER L, Bernhard L, Leha A, Kromer C, et al
    Checkpoint blockade and BRAF/MEK therapy in the therapeutic setting improved the overall survival after sentinel node biopsy: A retrospective study comparing patients with primary care between 1998-2009 and 2010-2017.
    Int J Cancer. 2023;153:380-388.
    >> Share

    June 2023
  11. FRAGALE A, Stellacci E, Romagnoli G, Licursi V, et al
    Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects.
    Int J Cancer. 2023 Jun 9. doi: 10.1002/ijc.34602.
    >> Share

    April 2023

  12. Erratum to "Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma".
    Int J Cancer. 2023 Apr 12. doi: 10.1002/ijc.34534.
    >> Share

    March 2023
  13. HEIKKINEN S, Demers PA, Hansen J, Jakobsen J, et al
    Incidence of cancer among Nordic police officers.
    Int J Cancer. 2023;152:1124-1136.
    >> Share

    February 2023
  14. VAN DUIN IAJ, Elias SG, van den Eertwegh AJM, de Groot JWB, et al
    Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.
    Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34479.
    >> Share

  15. DE MEZA MM, Blokx WAM, Bonenkamp HJ, Blank CU, et al
    Adjuvant Treatment of In-Transit Melanoma: Narrowing the Knowledge Gap Left by Clinical Trials.
    Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34485.
    >> Share

  16. DE FALCO V, Suarato G, Napolitano R, Argenziano G, et al
    Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: data from two Academic Italian Institutions.
    Int J Cancer. 2023 Feb 8. doi: 10.1002/ijc.34462.
    >> Share

    December 2022
  17. KUMAR N, Papillon-Cavanagh S, Tang H, Wang S, et al
    A multi-omic single cell sequencing approach to develop a CD8 T cell specific gene signature for anti-PD1 response in solid tumors.
    Int J Cancer. 2022;151:2043-2054.
    >> Share

    November 2022
  18. JAEHN P, Bergholz A, Holmberg C
    Regional inequalities of tumour size at diagnosis in Germany: An ecological study in eight federal states.
    Int J Cancer. 2022;151:1684-1695.
    >> Share

    August 2022
  19. SEEFRIED F, Haller L, Fukuda S, Thongmao A, et al
    Nuclear AREG affects a low-proliferative phenotype and contributes to drug resistance of melanoma.
    Int J Cancer. 2022 Aug 22. doi: 10.1002/ijc.34254.
    >> Share

  20. MAHAMAT-SALEH Y, Al-Rahmoun M, Severi G, Ghiasvand R, et al
    Baseline and lifetime alcohol consumption and risk of skin cancer in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC).
    Int J Cancer. 2022 Aug 19. doi: 10.1002/ijc.34253.
    >> Share

    June 2022
  21. ZAREMBA A, Jansen P, Murali R, Mayakonda A, et al
    Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors.
    Int J Cancer. 2022 Jun 23. doi: 10.1002/ijc.34187.
    >> Share

    April 2022
  22. CLAYTON B, Muneeb F, Hughes MCB, Grant ME, et al
    Hypothesised cutaneous sites of origin of stage III melanomas with unknown primary: a multi-centre study.
    Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34020.
    >> Share

    January 2022
  23. ELLEBAEK E, Schina A, Andersen R, Hendel HW, et al
    Clinical value of routine FDG-PET scans as a decision tool for early immunotherapy discontinuation in advanced melanoma.
    Int J Cancer. 2022 Jan 9. doi: 10.1002/ijc.33926.
    >> Share

  24. AAMDAL E, Jacobsen KD, Straume O, Kersten C, et al
    Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up.
    Int J Cancer. 2022;150:100-111.
    >> Share

    November 2021
  25. MARLEY AR, Li M, Champion VL, Song Y, et al
    Citrus-Gene Interaction and Melanoma Risk in the UK Biobank.
    Int J Cancer. 2021 Nov 1. doi: 10.1002/ijc.33862.
    >> Share

    October 2021
  26. LAI X, Zhou J, Wessely A, Heppt M, et al
    A disease network-based deep learning approach for characterizing melanoma.
    Int J Cancer. 2021 Oct 29. doi: 10.1002/ijc.33860.
    >> Share

  27. VAN NOT OJ, van Breeschoten J, van den Eertwegh AJM, Hilarius DL, et al
    The unfavorable effects of COVID-19 on Dutch advanced melanoma care.
    Int J Cancer. 2021 Oct 3. doi: 10.1002/ijc.33833.
    >> Share

    September 2021
  28. ROGAVA M, Braun AD, van der Sluis TC, Shridhar N, et al
    Tumor cell intrinsic TLR4 signaling promotes melanoma progression and metastatic dissemination.
    Int J Cancer. 2021 Sep 16. doi: 10.1002/ijc.33804.
    >> Share

  29. LIU W, Liu Y, Hu C, Xu C, et al
    Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
    Int J Cancer. 2021;149:1369-1384.
    >> Share

  30. VAN ZEIJL MCT, van den Eertwegh AJM, Wouters MWJM, de Wreede LC, et al
    Discontinuation of anti-PD-1 monotherapy in advanced melanoma - outcomes of daily clinical practice.
    Int J Cancer. 2021 Sep 14. doi: 10.1002/ijc.33800.
    >> Share

    May 2021
  31. ARROYO MUHR LS, Hultin E, Dillner J
    Transcription of Human Papillomaviruses in Non-Melanoma Skin Cancers of the Immunosuppressed.
    Int J Cancer. 2021 May 14. doi: 10.1002/ijc.33683.
    >> Share

    April 2021
  32. SUN Q, Novak D, Huser L, Poelchen J, et al
    FOXD1 Promotes Dedifferentiation and Targeted Therapy Resistance in Melanoma by Regulating the Expression of CTGF.
    Int J Cancer. 2021 Apr 9. doi: 10.1002/ijc.33591.
    >> Share

    February 2021
  33. BUCCHI L, Mancini S, Crocetti E, Dal Maso L, et al
    Mid-term trends and recent birth-cohort-dependent changes in incidence rates of cutaneous malignant melanoma in Italy.
    Int J Cancer. 2021;148:835-844.
    >> Share

    January 2021
  34. KOUTROS S, Decker KL, Baris D, Pardo LA, et al
    Bladder Cancer Risk Associated with Family History of Cancer.
    Int J Cancer. 2021 Jan 27. doi: 10.1002/ijc.33486.
    >> Share

  35. SACCHETTO L, Rosso S, Comber H, Bouchardy C, et al
    Skin Melanoma Deaths Within 1 Or 3 Years From Diagnosis In Europe.
    Int J Cancer. 2021 Jan 26. doi: 10.1002/ijc.33479.
    >> Share

  36. MONESTIER S, Dalle S, Mortier L, Dutriaux C, et al
    Effectiveness and Safety of Nivolumab in Patients with Advanced Melanoma: A Multicenter, Observational Study.
    Int J Cancer. 2021 Jan 11. doi: 10.1002/ijc.33467.
    >> Share

    December 2020
  37. CHOI J, Jia G, Wen W, Long J, et al
    Evaluating polygenic risk scores in assessing risk of nine solid and hematologic cancers in European descendants.
    Int J Cancer. 2020;147:3416-3423.
    >> Share

    November 2020
  38. DELLAC S, Ben-Dov H, Raanan A, Saleem H, et al
    Constitutive low expression of antiviral effectors sensitizes melanoma cells to a novel oncolytic virus.
    Int J Cancer. 2020 Nov 16. doi: 10.1002/ijc.33401.
    >> Share

    October 2020
  39. DAI WF, Beca J, Croxford R, Isaranuwatchai W, et al
    Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada.
    Int J Cancer. 2020 Oct 26. doi: 10.1002/ijc.33357.
    >> Share

    September 2020
  40. STALIN J, Traboulsi W, Vivancos-Stalin L, Nollet M, et al
    Therapeutic targeting of soluble CD146/MCAM with the M2J-1 monoclonal antibody prevents metastasis development and procoagulant activity in CD146-positive invasive tumors.
    Int J Cancer. 2020;147:1666-1679.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016